Clinical Trials Browser

Phase 2 × OTHER_GOV × anlotinib × Clear all

NCT07470840 2026-03-17

SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT04055792 2023-06-28

Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC

Phase 2 Completed

Neoplasm Metastasis

NCT04660097 2022-04-12

Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer

Phase 2 Unknown

Small Cell Lung Carcinoma